| |
| |
|
| Insider
Information: |
Lampert Mark N |
| Relationship: |
10% Owner |
| City: |
San Francisco |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
44 |
|
| Direct
Shares |
110,838,010 |
|
|
Indirect Shares
|
88,557,834 |
|
|
| Direct
Value |
$1,424,811,955 |
|
|
|
Indirect Value
|
$1,621,009,022 |
|
|
| Total
Shares |
199,395,844 |
|
|
| Total
Value |
$3,045,820,978 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
50
|
13
|
|
Stock
price went up :
|
40
|
4
|
| Stock
price went down : |
10
|
9
|
| |
|
|
|
Gain/Loss Ratio : |
4.0
|
4.0
|
| Percentage
Gain/Loss : |
 103.0%
|
 -82.1%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Arena Pharmaceuticals Inc |
ARNA |
Director, 10% Owner |
2003-10-17 |
0 |
2003-10-17 |
4,520,212 |
Premium* |
|
|
Repligen Corp |
RGEN |
10% Owner |
2009-05-15 |
3,216,850 |
|
0 |
Premium* |
|
|
Dynavax Technologies Corp |
DVAX |
Indirect Beneficial Ow... |
2009-06-19 |
6,193,051 |
2009-06-19 |
18,579,153 |
Premium* |
|
|
Adolor Corp |
ADLR |
10% Owner |
2009-09-22 |
4,123,551 |
2009-09-22 |
12,370,653 |
Premium* |
|
|
Gyre Therapeutics |
GYRE |
10% Owner |
|
0 |
2012-11-08 |
1,052,258 |
Premium* |
|
|
Arqule Inc |
ARQL |
10% Owner |
2018-05-30 |
771,305 |
2010-04-05 |
12,624,219 |
Premium* |
|
|
Astex Pharmaceuticals Inc |
ASTX |
10% Owner |
2010-04-20 |
5,583,399 |
2010-04-20 |
16,750,197 |
Premium* |
|
|
Capstone Therapeutics Corp |
CAPS |
See Explanation of Res... |
2011-06-27 |
0 |
2017-07-14 |
890,487 |
Premium* |
|
|
Ligand Pharmaceuticals Inc |
LGND |
See Explanation of Res... |
|
0 |
2014-03-25 |
130,175 |
Premium* |
|
|
Icagen Inc |
ICGN |
10% Owner |
2011-09-07 |
0 |
2011-09-07 |
625,400 |
Premium* |
|
|
Palatin Technologies Inc |
PTN |
10% Owner |
|
0 |
2014-02-27 |
2,494,521 |
Premium* |
|
|
Neurocrine Biosciences Inc |
NBIX |
10% Owner |
2011-10-10 |
0 |
2011-10-12 |
3,527,700 |
Premium* |
|
|
Kent International Inc |
KNTH |
See Explanation of Res... |
2011-12-23 |
0 |
2011-12-23 |
0 |
Premium* |
|
|
Chemocentryx, Inc. |
CCXI |
10% Owner |
|
0 |
2012-11-06 |
3,750,277 |
Premium* |
|
|
Rigel Pharmaceuticals Inc |
RIGL |
10% Owner |
|
0 |
2013-06-07 |
7,761,738 |
Premium* |
|
|
Cascadian Therapeutics, Inc |
CASC |
10% Owner |
2013-06-05 |
0 |
2015-02-05 |
1,898,293 |
Premium* |
|
|
Tobira Therapeutics Inc |
TBRA |
See Explanation of Res... |
|
0 |
2014-03-21 |
1,121,221 |
Premium* |
|
|
Cti Biopharma Corporation |
CTIC |
See Explanation of Res... |
2023-06-26 |
0 |
2023-06-26 |
0 |
Premium* |
|
|
Infinity Pharmaceuticals Inc |
INFI |
10% Owner |
2021-02-11 |
534,847 |
2016-12-01 |
0 |
Premium* |
|
|
XOMA Corporation |
XOMA |
Director, 10% Owner |
2023-01-06 |
1,693,924 |
2023-01-06 |
361,774 |
Premium* |
|
|
Alpine Immune Sciences Inc |
ALPN |
10% Owner |
2017-06-20 |
201,811 |
2017-05-09 |
0 |
Premium* |
|
|
Glycomimetics Inc |
GLYC |
10% Owner |
2020-11-04 |
630,453 |
|
0 |
Premium* |
|
|
Xenon Pharmaceuticals Inc. |
XENE |
10% Owner |
2018-03-27 |
59,464 |
2017-06-06 |
0 |
Premium* |
|
|
Concert Pharmaceuticals, Inc. |
CNCE |
10% Owner |
2019-06-10 |
169,589 |
2017-10-19 |
0 |
Premium* |
|
|
Syndax Pharmaceuticals Inc |
SNDX |
10% Owner |
2018-06-18 |
85,038 |
2018-06-18 |
0 |
Premium* |
|
|
Immune Design Corp. |
IMDZ |
10% Owner |
2018-12-04 |
370,391 |
2018-12-04 |
0 |
Premium* |
|
|
Pieris Pharmaceuticals, Inc. |
PIRS |
10% Owner |
2023-05-11 |
20,333,557 |
2019-01-30 |
0 |
Premium* |
|
|
Calithera Biosciences, Inc. |
CALA |
10% Owner |
2020-05-21 |
480,432 |
|
0 |
Premium* |
|
|
Five Prime Therapeutics Inc |
FPRX |
10% Owner |
2021-03-04 |
6,262,085 |
|
0 |
Premium* |
|
|
Cytokinetics Inc |
CYTK |
See Explanation of Res... |
2020-12-09 |
463,244 |
2019-12-10 |
0 |
Premium* |
|
|
Merus Nv |
MRUS |
10% Owner |
2021-10-08 |
232,747 |
|
0 |
Premium* |
|
|
Ideaya Biosciences, Inc. |
IDYA |
See Explanation of Res... |
2021-02-02 |
233,150 |
2020-06-19 |
0 |
Premium* |
|
|
Kymera Therapeutics, Inc. |
KYMR |
See Remarks and Footno... |
2023-11-03 |
294,632 |
2020-08-21 |
0 |
Premium* |
|
|
Eledon Pharmaceuticals Ord Shs |
ELDN |
10% Owner |
2024-05-09 |
220,460 |
|
0 |
Premium* |
|
|
Olema Pharmaceuticals, Inc. |
OLMA |
Director, 10% Owner |
2023-09-12 |
524,151 |
2023-09-14 |
99,556 |
Premium* |
|
|
Cytomx Therapeutics, Inc. |
CTMX |
10% Owner |
2020-12-18 |
5,468,599 |
|
0 |
Premium* |
|
|
Rain Therapeutics Inc. |
RAIN |
See Remarks; Former 10... |
2024-01-25 |
0 |
2021-04-23 |
0 |
Premium* |
|
|
Repare Therapeutics Inc. |
RPTX |
10% Owner |
2023-11-16 |
548,938 |
|
0 |
Premium* |
|
|
Verastem, Inc. |
VSTM |
10% Owner |
2022-01-25 |
19,630,934 |
|
0 |
Premium* |
|
|
ESSA Pharma Inc |
EPIX |
10% Owner |
2022-07-11 |
8,561,841 |
|
0 |
Premium* |
|
|
Third Harmonic Bio, Inc. |
THRD |
10% Owner |
2022-12-20 |
241,309 |
2022-12-20 |
0 |
Premium* |
|
|
Structure Therapeutics Inc. |
GPCR |
10% Owner |
2023-05-10 |
5,173,941 |
|
0 |
Premium* |
|
|
Engene Holdings Inc. |
ENGN |
10% Owner |
2023-10-31 |
2,221,445 |
|
0 |
Premium* |
|
|
Allakos Inc. |
ALLK |
10% Owner |
2024-01-16 |
16,312,872 |
|
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| ARQL |
Arqule Inc |
10% Owner |
– – • |
2017-10-11 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
21,912,742 |
|
- |
|
| PIRS |
Pieris Pharmaceuticals, I... |
10% Owner |
– – • |
2023-05-11 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
20,333,557 |
|
% |
|
| VSTM |
Verastem, Inc. |
10% Owner |
– – • |
2022-01-25 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
19,630,934 |
|
% |
|
| CTIC |
Cti Biopharma Corporation |
10% Owner |
– – • |
2016-01-08 |
4 |
B |
$1.22 |
$71,338 |
I/I |
58,613 |
17,263,200 |
1.5 |
- |
|
| CTIC |
Cti Biopharma Corporation |
10% Owner |
– – • |
2016-01-07 |
4 |
B |
$1.22 |
$9,848 |
I/I |
8,091 |
17,204,587 |
1.5 |
- |
|
| ALLK |
Allakos Inc. |
10% Owner |
– – • |
2024-01-16 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
16,312,872 |
|
% |
|
| ARQL |
Arqule Inc |
10% Owner |
– – • |
2017-10-11 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
14,207,911 |
|
- |
|
| ARQL |
Arqule Inc |
10% Owner |
– – • |
2017-10-11 |
9 |
IO |
$0.00 |
$0 |
D/D |
0 |
14,207,911 |
|
% |
|
| GPCR |
Structure Therapeutics In... |
10% Owner |
– – • |
2023-02-03 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
12,584,459 |
|
- |
|
| RIGL |
Rigel Pharmaceuticals Inc |
10% Owner |
– – • |
2013-05-01 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
9,697,997 |
|
- |
|
| CASC |
Cascadian Therapeutics, I... |
10% Owner |
– – • |
2014-12-12 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
9,282,532 |
|
- |
|
| ARQL |
Arqule Inc |
Direct Beneficial Owner |
– – • |
2009-09-17 |
4 |
S |
$5.25 |
$19,320,000 |
D/D |
(3,680,000) |
8,564,073 |
0 |
- |
|
| EPIX |
ESSA Pharma Inc |
10% Owner |
– – • |
2022-07-11 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
8,561,841 |
|
- |
|
| CASC |
Cascadian Therapeutics, I... |
10% Owner |
– – • |
2013-06-04 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
7,837,978 |
|
- |
|
| CYTK |
Cytokinetics Inc |
10% Owner |
– – • |
2019-12-09 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
6,636,638 |
|
- |
|
| INFI |
Infinity Pharmaceuticals ... |
10% Owner |
– – • |
2018-12-13 |
4 |
B |
$1.20 |
$209,913 |
D/D |
175,000 |
6,631,136 |
2.45 |
- |
|
| CALA |
Calithera Biosciences, In... |
10% Owner |
– – • |
2019-06-19 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
6,526,004 |
|
- |
|
| INFI |
Infinity Pharmaceuticals ... |
10% Owner |
– – • |
2018-11-28 |
4 |
B |
$1.30 |
$130,000 |
D/D |
100,000 |
6,510,597 |
2.45 |
- |
|
| FPRX |
Five Prime Therapeutics I... |
10% Owner |
– – • |
2021-03-04 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
6,262,085 |
|
- |
|
| ADLR |
Adolor Corp |
Indirect Beneficial Owner |
– – • |
2009-06-19 |
4/A |
S |
$2.00 |
$42,970 |
D/D |
(21,500) |
6,193,051 |
0 |
- |
|
| DVAX |
Dynavax Technologies Corp |
Indirect Beneficial Owner |
– – • |
2009-06-19 |
4 |
S |
$2.00 |
$42,970 |
D/D |
(21,500) |
6,193,051 |
0 |
- |
|
| ARQL |
Arqule Inc |
10% Owner |
– – • |
2010-03-31 |
4 |
S |
$6.24 |
$16,475,712 |
D/D |
(2,640,000) |
5,924,073 |
0 |
- |
|
| INFI |
Infinity Pharmaceuticals ... |
10% Owner |
– – • |
2018-11-15 |
4 |
B |
$1.35 |
$123,490 |
D/D |
91,474 |
5,815,887 |
2.45 |
- |
|
| INFI |
Infinity Pharmaceuticals ... |
10% Owner |
– – • |
2018-11-14 |
4 |
B |
$1.34 |
$281,735 |
D/D |
210,250 |
5,776,813 |
2.45 |
- |
|
| ASTX |
Astex Pharmaceuticals Inc |
Direct Beneficial Owner |
– – • |
2010-04-19 |
4 |
S |
$3.58 |
$236,049 |
D/D |
(66,000) |
5,687,399 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
